Clinical Trials Logo

Clinical Trial Summary

To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Moderate or Severe Submental Fullness

NCT number NCT01542034
Study type Interventional
Source Kythera Biopharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date February 2012
Completion date August 2013

See also
  Status Clinical Trial Phase
Completed NCT01546142 - Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area Phase 3
Completed NCT05266729 - Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area Phase 2
Completed NCT03982225 - Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat Phase 2
Completed NCT01294644 - Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat Phase 3
Completed NCT02007434 - Patient Experience Study of Deoxycholic Acid Injection Phase 3
Completed NCT01305577 - Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat Phase 3
Completed NCT01032889 - Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study Phase 2
Completed NCT01426373 - Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area Phase 3
Completed NCT00618722 - Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat Phase 1/Phase 2
Completed NCT00618618 - Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat Phase 2